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In 2011, the International Society of Geriatric Oncology (SIOG) published The SIOG 10 Priorities Initiative 
defining top priorities for the improvement of the care of older adults with cancer worldwide1. 
Significant scientific, clinical, and educational progress has been made in line with these priorities. In 
parallel, international health policy developments have occurred, such as the shift of emphasis by the 
World Health Organization from communicable to non-communicable diseases, and the adoption by the 
United Nations of its Sustainable Development Goals 2030. Therefore, SIOG has thought timely to 
update its priority list. The present document addresses four priority domains: Education, Clinical 
Practice, Research, and Collaborations/Partnerships. It includes input from SIOG members and from 
extensive consultations with partners across the world. SIOG hopes that it will offer guidance for 
international and national endeavors to provide adequate Universal Health Coverage for older adults 
with cancer, a major and rapidly growing group in global epidemiology.      




In 2011, the International Society of Geriatric Oncology (SIOG) published The SIOG 10 Priorities Initiative 
to define the top priorities for the advancement of geriatric oncology worldwide 1,2. As the only global 
expert multidisciplinary organization dedicated to the care of older people with cancer, SIOG created a 
tool to guide policy making, and development of education, clinical practice and research. This 
document has been very favorably received and used in different jurisdictions around the globe (e.g.3-6). 
Since 2011, a significant amount of progress has been made in the field of geriatric oncology. SIOG and 
other expert societies have developed guidelines and consensus statements based on up to date clinical 
research to provide evidence-based care for older people with cancer7,8. Geriatric oncology programs 
have multiplied, although in an uneven fashion. For example some countries have multiple programs in 
organized systems, and others only a few programs stemming from local initiatives, and there is a large 
diversity of organizational models. Training courses such as the SIOG Treviso course have been 
established9.  
Nonetheless, there is still a pressing need to continue the development of initiatives to improve the 
quality of cancer care for older adults, and to translate them into broad standards of care. The World 
Report 2015 on Ageing and Health estimates that the number of people over 60 years of age will double 
by 205010. In addition, over the last decade – as life expectancy has increased worldwide – chronic 
diseases such as cancer have become a major public health issue in both high income countries (HICs) 
and low/middle income countries (LMICs). This has prompted the World Health Organization (WHO) to 
refocus its activities toward non-communicable diseases. A prominent step forward has been the ICOPE 
(Integrated Care for Older People) guidelines coordinated by the WHO Department of Ageing and Life 
Course for implementation of patient-centered care11. In 2015, the United Nations adopted the 2030 
Agenda for Sustainable Development, which includes 17 Sustainable Development Goals (SDG; 
https://sustainabledevelopment.un.org/?menu=1300, accessed 2 Nov 2019). Goal number 3 (SDG3) in 
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this agenda addresses health issues. Several points are particularly relevant to the cancer care of older 
adults (Table 1).  
Therefore SIOG recognized the need to update its 10 Priorities Initiative. The Society deems it timely to 
invest in better understanding of the SDG3 challenges and priorities, to catalyze integrated and 
collaborative efforts, to guide appropriate financial and human resources allocation, and to advocate for 
quality in cancer services for the older adults within the goal of Universal Health Coverage (UHC).  
In this update, the three initial categories of education, clinical practice and research have been 
enhanced by the addition of a section on collaborations and partnerships. Each section also now 
includes a reflection on how these priorities would apply in different economic settings, namely HICs 
and LMICs12.  
 
Methods An international multidisciplinary working group was established at the end of 2018 
representing medical oncology, geriatrics, surgery, radiation oncology, anesthesiology, nursing, and 
patient advocacy.  Input was sought from international health organizations, professional societies, and 
patient groups/consumers. Expanding on the framework of the 10 Priorities Initiative, this SIOG Working 
Group consulted the SIOG 35 national representatives as well as various governmental and non-
governmental organizations (see Acknowledgments). The group had several in person and electronic 
meetings. Working subgroups initiated drafts and priorities on the 4 main sections (education, clinical 
practice, research, collaborations and partnerships). The manuscript was then integrated, reviewed, and 
went through several iterations until consensus was met. This first draft  was then circulated for a 
second round of external feedback, before finalizing the present document. Where appropriate, we 
have drawn parallels with the SDG3 (Table 1).  
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Search strategy and selection criteria: This consensus article did not include a specific systematic review 
of literature. All SIOG national representatives, a large number of international organizations, and 
representatives of national health authorities were contacted. Their input was incorporated in the task 




Priority 1: Integrate geriatric oncology into medical, nursing, and allied health professionals school 
and residency training programs, and promote involvement of trainees in research. 
Since all health care workers treating patients with cancer will be treating older patients to an increasing 
extent, a core set of required geriatric skills shall be formulated and integrated into general oncology 
training programs for physicians, nurses and allied health professionals. Conversely an oncology module 
should become an integral part of geriatric training. Key components of the education should include 
changes in cancers and patient biology and function with aging, the value of a geriatric assessment as 
time well spent in managing these patients, evidence-based personalization of treatment options 
including both tumor and patient characteristics, and integration of patient-generated goals of care. 
These should cover prevention, early diagnosis, management, rehabilitation, and end-of-life 
management of cancer in older adults, and understanding both the patients and their family various 
needs, including physical, psychological, social and financial ones13. 
Young clinicians and researchers in geriatric oncology, including nurses and allied healthcare 
professionals, should be supported by facilitating mentorships, international exchange, and 
scholarships. SIOG and other international organizations should strive to establish educational global 
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networks, programs, and teaching collaborations between leading institutions in geriatric oncology, in 
order to support less experienced institutions trying to initiate or develop geriatric oncology programs in 
their environment (see also Priorities 6 and 10). 
Although the availability of resources may vary between HICs and LMICs, such training should be offered 
in both settings. Training programs should be adapted to the local resources and needs, and may 
leverage remote-learning opportunities offered by rapid progress in technology in order to broaden the 
reach of centers of expertise.  
 
Priority 2: Provide educational material and organize formal educational activities focused on geriatric 
oncology for practicing health care professionals.  
Continuing education after completion of baseline professional education is a key training component to 
ensure an impetus for change in clinical practice. Educational activities should be targeted for a broad 
range of professionals. Geriatric oncology sessions and workshops should be emphasized in national and 
international meetings. Training should be delivered at general oncology and general geriatric, as well as 
geriatric oncology specific meetings. The key contents should include the items mentioned in Priority 1. 
The training should harness the patient and caregiver experiences and expertise. A strong patient 
advocacy educational component needs to be developed in communities/regions where such advocates 
are scarce, or do not exist.  
In LMICs, resource-stratified adaptations may be required to surmount economic difficulties for 
attending educational meetings. One potential method is “train the trainer” partnerships whereby key 
individuals from a LMIC may undergo training at established centers of excellence. Post training, these 
individuals will be expected to return to their country of origin to develop and apply their new skills 
there, becoming local educational leaders. Geriatric oncology experts can also be sent to LMICs to train 
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key individuals who can then be trainers within their respective communities. Free educational 
opportunities for frontline community healthcare workers are particularly relevant in LMICs, since they 
can increase awareness about geriatric principles and strengthen the capacity of healthcare systems to 
provide high-quality care for older adults with cancer.   
Wherever possible, digital opportunities for education, including e-learning, online conference lectures, 
social media, webinars, podcasts, web-based tools, and mobile applications should be harnessed to 
disseminate knowledge of geriatric oncology to a broader public. These strategies could prove 
particularly useful for clinicians working in LMICs, for whom attendance at courses or conferences might 
be challenging (e.g. because of cost, travel, language barriers). Translation of evaluation instruments and 
education materials in various languages should be promoted and strongly supported as a way to 
remove barriers to access.   
 
Priority 3: Educate the general public about the relevance of providing age-appropriate care for older 
adults with cancer.  
The worldwide increase in life expectancy is a recent phenomenon and is accompanied by 
improvements in general health, function, and quality of life of older people. Social perceptions have yet 
to adapt to these facts however, and both images of successful aging and opportunities for oncologic 
management are not well known to the general public, or even medical professionals, which can lead to 
stereotyping and discrimination (ageism). Therefore an outreach to the general public and to political 
authorities is needed. Maintenance of independence and the ability to meaningfully contribute to 
society are a core goal of age appropriate cancer care. . This requires educating the public on common 
facts: occurrence of cancer and other chronic diseases in older people, the need for, and feasibility of, 
specific care in this population, issues of under- and over- treatment , specific needs or aims expressed 
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by older adults, etc. In addition, efforts must be made to focus public messages on healthy aging and on 
the active involvement of older adults in society, as well as on the fact that expenditure for the health 
and well-being of older populations represents an investment, rather than a cost.  Research and care 
improvement actions need to be highlighted publicly through adequate communication channels, with 
specific aids (wording, self-explanatory figures, hearing/visually impaired access, etc.), to reach out to 
the general audience, call for advocacy, and eventually contribute to the push for age-appropriate care. 
Community education campaigns about the importance of understanding the unique needs of older 
adults with cancer and of providing awareness of the risk of ageism in health care are essential 




Priority 4: Develop and implement models to provide optimal care for older adults with cancer. 
Multidisciplinary patient-centered care for all older adults with cancer is necessary to achieve optimum 
goals. Although different non-exclusive models exist, teams organizing care for older patients must 
include both oncology and geriatric specialists. In some clinical healthcare organizations, the geriatric 
expertise brought to the oncologists is part of the supportive care program, while in others it is fully 
integrated within the oncology activity or established as a strong collaboration between departments or 
institutions. In other settings the resources of telemedicine could be leveraged for integrated tumor 
boards and consultations. Geriatric oncology principles (minimum standards) should be applied to older 
adults across all resource settings, regardless of stage in the cancer trajectory. This includes the 
performance of some form of geriatric screening and/or assessment to identify potential age-related 
problems and integrate it in the (electronic) medical record. The results of the geriatric assessment 
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should help in making informed treatment choices (e.g. by predicting the chance of severe 
chemotherapy-related toxicity)14 and guide integrated geriatric and supportive care interventions for 
any detected health problems. Shared decision-making should include not only the patient, but also 
his/her caregiver(s).  
The degree of integration of oncogeriatric interventions and opportunities for geriatric input/care into 
the oncology setting will differ depending upon the resources available. Therefore, different approaches 
may be required in HICs than in LMICs as well as according to practice size and setting. Importantly, the 
definition of older age will differ according to the health care setting in which it is applied15. Use of 
concepts like the 4M’s (What Matters, Medicine, Mentation, and Mobility)16 can be useful in designing 
“age-friendly” services regardless of the resource setting.  
The provision of optimal cancer care for older adults will be best achieved in age-friendly health systems 
(AFHS) that provide UHC for all, regardless of the patients’ ability to pay. The financial coverage for a 
geriatric assessment by a geriatrician or by an oncologist or another health-care provider trained to 
conduct such assessment should be promoted by state health policy as an essential health-care service 
for access to safe, high-quality, and effective treatment for older adults with cancer. 
  
 
Priority 5: Develop guidelines for the optimal treatment of older adults with cancer.  
The development of evidence-based guidelines specific to older adults with cancer is important to 
facilitate clinical practice improvements regardless of the resource setting in which they are applied. 
SIOG produces resource-stratified and multi-disciplinary guidelines applicable globally for specific 
oncological diseases, strategies and situations. These or other geriatric oncology guidelines should be 
applied in all clinical settings. Guidelines should recognize that care of older adults is 
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multi/interdisciplinary and be written for all clinicians in the cancer care team. Their use should be 
monitored and updated regularly. 
Guidelines should cover the whole spectrum of needs: treatment choice and management; toxicity 
prevention; approaches according to specific tumor types; geriatric assessment and interventions; 
rehabilitation; cancer screening and prevention; diagnostics, and survivorship. These guidelines should 
highlight evidence specific to older adults with cancer, when available. When recommendations are 
based on general clinical trials, they should acknowledge the lack of specific data for the older 
population, wherever appropriate, and highlight the need for constant therapeutic strategy 
adjustments, including the possibility of de-escalation. Furthermore, guidelines should indicate in which 
areas there is the greatest need to establish new evidence specific for older adults with cancer17. 
Collaboration among international and national cancer organizations that produce highly acknowledged 
guidelines should be sought, aiming to incorporate the geriatric aspect in all future general oncology 
guidelines. Discussions for adaptation to meet the needs of the LMICs, as well as underserved areas in 
HICs, should be included, taking as a guide the WHO list of essential medicines18. Evidence-based 
proposals may be included beyond this list, particularly for high-benefit drugs of significant relevance for 
older patients.    
 
Priority 6: Establish centers of excellence in geriatric oncology for delivering clinical care, conducting 
clinical and translational research, and providing educational opportunities. 
Progress made during the last two decades has led to the creation and implementation of highly 
successful geriatric oncology facilities across the world, most of these located in Western Europe and 
North America. Their numbers should be expanded and further developed into geriatric oncology 
centers of excellence, which not only can provide high-quality clinical care but also offer training and 
research initiatives as local and regional leaders. In HICs, the goal should be to implement these 
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specialized units in all major academic medical centers. In LMICs, the initial goal should be to develop at 
least one such center nationally. In some LMICs, oncology services at specialized tertiary-level cancer 
centers may exist and geriatric oncology expertise can be created. These facilities should build upon the 
experience from their counterparts in HICs, as well as upon existing initiatives and lessons learnt in other 
LMICs through collaborations to provide integrated people-centered health services. In other cases, a 
“train the trainer” approach (see Priority 2) may be used to develop geriatric oncology expertise 





Priority 7: Improve the relevance of clinical trials to older adults with cancer. 
The highest priority for research in geriatric oncology in both HICs and LMICs is to improve the 
relevance of clinical trials for older adults with cancer. Clinical trials should include this population in all 
treatment modalities, and promote enrollment from all ethnic/racial backgrounds.  
Older adults are still underrepresented in clinical trials and those included often belong to a relatively 
healthy subgroup, due to restrictive eligibility criteria17,19-21. Less fit older adults and those with 
comorbidities may be limited in their ability to tolerate treatment or may be more likely to die from 
causes other than cancer. This may result in more toxicity or treatment-related complications and less 
significant treatment benefit compared to a younger, healthier population.  For optimal tailoring of 
care for older adults with cancer, it is crucial that the evidence base guiding treatment decisions is 
expanded by broadening eligibility criteria of clinical trials22. Older adult-specific trials (with or without 
randomization, where appropriate) are needed when evidence from general trials is insufficient, in 
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particular for patients with multimorbidity and frailty. Translational research should be included to 
understand the changes in cancer biology and host-tumor interaction with age, comorbidity, and 
ethnicity. If such trials are not feasible, representative cohort studies may be conducted provided that 
the appropriate methodology is used to gain meaningful, statistically sound information.  
 
Additionally, integrating a geriatric assessment into clinical trials would not only provide a much better 
understanding of the health status of the study population, but also allow for subgroup analyses as 
well as stratified accrual based on geriatric variables. Reaching a consensus on a core of selected 
geriatric data to share systematically across countries and culture would help to compare results and 
improve analysis and applicability of results to various settings. Potential sets could be the G-CODE 
initiative led by the French DIALOG intergroup23, the geriatric assessment panel used by the Alliance 
and American cooperative groups24, or by the EORTC25. Accrual may prove an issue irrespective of 
study design; therefore, encouraging older adults with cancer to participate in studies is an essential 
component for improving the evidence base in geriatric oncology.   
Another important need is the inclusion of patient-centered outcome measures relevant to older 
adults, including patient-reported outcomes (PROs) and geriatric-specific outcomes26. Health-related 
quality of life (QoL), cognitive and physical functioning, care dependence, and caregiver burden should 
be given equal importance to the more traditional outcome measures such as efficacy and treatment-
related toxicity, since for many older patients, maintaining QoL and independence are at least as 
important, if not more so, as survival itself26. Most research focusing on geriatric oncology and PROs 
has been done in HICs. Racial/ethnic background and cultural differences may affect patient priorities 
and how various PROs are valued. Therefore, additional efforts should be made to define which PRO 
measures are most relevant in LMICs and across racially and culturally diverse populations. Finally, 
Extermann et al. 14 
 
 
more research in humanities addressing social and personal aspects influencing trial and treatment 
participation should be conducted.  
It should be further noted that trial design, feasibility, and the assurance of patient-centered goals can 
be greatly enhanced by the engagement of patients, caregivers, patient advocates and other 
stakeholders as partners in the research process. The value of their inclusion is well documented (in 
the US) in the experience of the Patient Centered Outcomes Research Institute (PCORI) and the 
National Cancer Institute National Clinical Trials Network Steering Committees (NCINCTNSC), among 
others27-29. 
 
Priority 8: Evaluate the benefits of geriatric assessment-allocated treatments and geriatric co-
management in improving treatment outcomes for older adults with cancer. 
Geriatric instruments and definitions of frailty for use in the oncology setting should be operationalized 
to guide treatment selection and interventions. Geriatric instruments can be questionnaires or in 
person tests for geriatric problems. Definitions of frailty aim at identifying key parameters that indicate 
a patient has a decreased functional reserve and is at increased risk of complications. Examples of such 
tools can be found at http://www.siog.org/content/comprehensive-geriatric-assessment-cga-older-
patient-cancer or references30,31. Since the publication of the 2011 SIOG 10 Priorities Initiative, much 
work has been done in increasing the evidence base regarding the value of the geriatric assessment in 
evaluating a patient’s health status, identifying previously unrecognized health problems that may be 
relevant for treatment decisions, and providing an overall assessment of the level of frailty.30,31 In 
addition, multiple studies have demonstrated that awareness of frailty and geriatric impairments often 
leads to changes in the oncologic treatment plan.14,32   Future studies should assess the impact of 
geriatric assessment and co-management on outcomes, as well as their use for treatment 
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stratification. Early results of four RCTs showing an impact on treatment tolerability, quality of life, and 
hospitalizations were recently presented33-36. 
This research will require operationalization and standardization of geriatric instruments and 
definitions of frailty specifically for the oncology setting. Although this is an area of active investigation, 
we do not believe we have yet tools that solidly report frailty for use in oncology decision making with 
actionable thresholds. It should also be acknowledged that frailty tools in oncology may be in some 
way different from frailty tools in the non-cancer older population because of the underlying impact of 
the cancer. For LMICs, this may also require either cultural and/or linguistic adaptations of tools 
existing in HICs, or the development of novel tools or measurements adapted to local characteristics. 
Large randomized trials designed to demonstrate the impact of geriatric assessment-guided 
interventions in oncology remain a high priority, since such oncology-specific data would greatly 
improve the rate of adoption of geriatric principles in the oncology community, as well as establish the 
most effective ways to implement comprehensive management.  
To study stratification strategies, trials are needed that compare treatment outcomes between 
geriatric assessment-based allocation and standard treatment allocation (based on clinical judgment, 
chronologic age, and/or performance status). This may also include strategies that address optimal 
allocation of limited oncological resources. Furthermore, such research should include the possibility of 
using multidisciplinary interventions aimed at issues identified by the geriatric assessment to improve 
the patient’s health status, their ability to tolerate treatment, and treatment outcomes. Success in 
disseminating the value of geriatric assessment and management for older adults with cancer and in 
leveraging the oncology community will come only through such stepwise and clear-cut 
demonstration. 
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Priority 9: Utilize personalized medicine technologies to enhance the precision of cancer 
understanding and management in older adults. 
Harnessing the synergistic potential of basic and translational research in both cancer and aging retains 
its importance as a research priority. This includes understanding the interaction between cancer, 
cancer treatment, and age: how does age affect carcinogenesis and how does cancer treatment affect 
aging. Furthermore, biomarkers of aging potentially could be used to determine physiological reserve37, 
which is relevant to prognosis as well as treatment tolerance.  
In addition, big data analyses leveraging Artificial Intelligence and Machine Learning techniques are 
required to identify patterns of aging, comorbidity, and cancer, and to identify groups for tailored 
approaches. While the rapidly developing “–omics”  provide opportunities for understanding cancer and 
aging on a cellular and organism level, big data and real-world data may be used to increase 
understanding of these processes on a population level. It remains essential to combine these types of 
data with clinical information derived from geriatric assessments in order to take all relevant domains 
into account. Big Data could be used to provide real time on-demand case references for treating older 
adults with complex cancer and comorbidity presentations. Data from wearable technologies could 
provide unique opportunities to track the impact of treatment on older adults with cancer and design 
targeted interventions. Integration with large epidemiologic datasets such as those of the Global Burden 
of Disease study could further enhance public health approaches to this issue15.   
 
-Collaborations & partnerships 
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Priority 10: Develop and strengthen links between SIOG & the geriatric oncology work force, 
international specialized agencies, global and regional professional organizations, policy makers, and 
patient advocacy groups. 
Many healthcare systems are ill-prepared to face an aging population due to a lack of training, 
personnel, and resources. Partnerships with specialized agencies, global and regional professional 
organizations, and patient advocacy groups could help bring geriatric oncology to the forefront and 
highlight its relevance for the future not only of cancer care, but of healthcare in general. These 
collaborations should be carried out on a national, regional, and global scale, with equal participation 
from geriatric oncology stakeholders in HICs and LMICs, and with the ultimate goal of achieving UHC and 
meeting the SDG targets by 2030.  
Countries need to find innovative financing and cross-sectoral accountable partnership mechanisms 
encompassing global-local, public-private and industry-academia, in order to increase investments for 
practical and cost-efficient solutions to this priority health care challenge. Patient advocacy can help 
garner political support for  making an economic case to governments and the private sector for shifting 
from a cost to an investment perspective.  
Global and regional public health agencies, including the WHO and its regional offices, should include 
integration of the provision of cancer care for older adults into initiatives aimed at the creation of AFHS. 
Additionally, regional and national agencies in charge of evaluating medicinal products and devices, such 
as the European Medicines Agency and the Food and Drug Administration, should strive to mandate the 
inclusion of relevant and representative quotas of older adults in registration clinical trials, and for the 
development of older-adult specific research for the approval of novel medicines, as mentioned in 
Priority 7.  
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For education (see priority 2 also), official collaborations through Memoranda of Understanding (MoUs), 
contracts, calls for scholarships or fellowships, etc., should be increased and strengthened with 
Universities. SIOG has established templates for such memoranda. Collaborations with organizations 
such as the World Federation for Medical Education and the International Council of Nurses would be 
helpful to integrate courses or modules on geriatric oncology into the general physician and nursing 
curriculums. 
The involvement of older patients and their caregivers through advocates and patient organizations 
should be expanded at all levels of this global initiative (e.g. education, research, policy) supported by 
appropriate reimbursements.  
 
Priority 11: Promote the inclusion of specific provisions for delivering high-quality evidence-based 
care for older adults in national cancer control plans. 
The issue of cancer care for older adults is universal and represents an epidemiological challenge in need 
of political commitment at a global level. Meeting this challenge should be a priority for national 
healthcare systems worldwide, and should be included in national cancer care plans. Countries should 
create policies which aim at providing UHC for older adults with cancer, and at integrating oncology and 
geriatric training and competencies in health workforce training as stated in Priority 1. These policies 
should facilitate the application of geriatric assessment and management, and mobilize all stakeholders, 
including health insurance and public and private agencies, to broaden financial coverage and address 
education needs.   
For HICs, this may include supporting integrated national healthcare systems in which teams of 
geriatricians, oncologists, and other healthcare professionals with geriatric training and expertise 
provide care for older adults with cancer. The reimbursement of geriatric assessments and interventions 
for older adults with cancer should also be ensured.  
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For LMICs, this may include the development or creation of cancer registries to better understand the 
epidemiology of cancer in older adults and to foster the development of core national centers of 
expertise. There is also need to create social protection schemes to reduce out-of-pocket spending for 
older adults with cancer. National governments should ensure access to essential cancer medicines, 
including those required for palliative and supportive care, relying on the WHO Model List of Essential 
Medicines List.  
 
Priority 12: Create global funding mechanisms aimed at fostering professional development of the 
geriatric oncology workforce and promoting research on the interface of cancer and aging.  
Global, regional, and national public funding organizations should prioritize the funding of 
multidisciplinary basic, clinical, and translational research aimed at improving the care of older adults 
with cancer. However, public funding ability to obtain substantial matching support from the private 
sector is limited by the absence of a market for such private sector investment in most contexts. Health 
care systems should work towards creatively setting new models of collaboration with the private 
investment sector. The pharmaceutical industry should support research initiatives testing novel drugs, 
devices and equipment systems for older adults with cancer. If this does not occur spontaneously, it 
should be formally requested and incentivized by governments and reimbursement organizations.  
Funding and other incentives should be provided by governments to increase the number of healthcare 
workers who enroll in training programs in geriatrics, oncology, and geriatric oncology. In LMICs, 
economic incentives for the retention of geriatric oncology specialists should be provided in order to 
avoid a brain drain and increase the availability of cancer care providers with geriatric training and 
expertise. Development of research collaborations with HICs is desirable not only to develop local 
infrastructure, but also to achieve “reverse” or “trickle-up” innovation, through which research and 
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models of care developed in LMICs can be translated to healthcare settings in HICs. These collaborations 
should be equitable, avoiding “parasitic” research. Support funding should also be provided for young 





In this document, we provide a broad expert consensus on 12 priorities to advance the care of older 
adults with cancer on a global scale. We strive to harmonize these priorities with other global agendas, 
notably UHC and SDG3.4. We welcome the UN declaration on UHC at the UN General Assembly 
(September 23, 2019), and pay particular attention to how the priorities might be implemented in both 
HICs and LMICs. The aging of the world population is one of the key challenges of 21st century medicine 
and improvement in cancer care will only be achieved by close collaboration between medical societies 
and institutions, governmental agencies, private industry, media, and global health organizations, 
including patient advocacy groups. The commitment of UN members to achieving UHC is a key means 
for offering equitable cancer care to older adults, who represent a large and growing segment of the 
cancer population.  
SIOG has chosen ambitious and visionary objectives to establish multidimensional, interdisciplinary 
processes to optimize the health and well-being of older patients with or without multimorbidities. The 
SIOG Top Priorities Initiative fits into much broader and long-term achievements of SIOG and its 
partners and worldwide efforts that have been progressing for more than a decade. We intend to 
ensure that the ongoing works of SIOG and its partners meet international goals and will have impact 
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well beyond the UN 2030 Agenda. This can be achieved by building even larger, more sustainable 
international networks for ultimately attaining ‘worldwide health for all’. 
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Table 1: Extracts from the United Nations Sustainable Development Goals document, goals 3: Good 
Health and well-being. 
• 3.4 By 2030, reduce by one third premature mortality from non-communicable diseases through 
prevention and treatment and promote mental health and well-being. 
• 3.8 Achieve universal health coverage, including financial risk protection, access to quality 
essential health-care services and access to safe, effective, quality and affordable essential 
medicines and vaccines for all. 
• 3.A Strengthen the implementation of the World Health Organization Framework Convention on 
Tobacco Control in all countries, as appropriate. 
• 3.C Substantially increase health financing and the recruitment, development, training and 
retention of the health workforce in developing countries, especially in least developed 
countries and small island developing States. 
• 3.D Strengthen the capacity of all countries, in particular developing countries, for early 
warning, risk reduction and management of national and global health risks. 
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Priority 1: Integrate geriatric oncology into medical, nursing, and allied health professionals schools 
and residency  training programs, and promote involvement of trainees in research. 
Priority 2: Provide educational material and organize formal educational activities focused on geriatric 
oncology for practicing health care professionals.  
Priority 3: Educate the general public about the relevance of providing age-appropriate care for older 
adults with cancer.  
Clinical practice 
 
Priority 4: Develop and implement models to provide optimal care for older adults with cancer. 
Priority 5: Develop guidelines for the optimal treatment of older adults with cancer.  
Priority 6: Establish centers of excellence in geriatric oncology for delivering clinical care, conducting 
clinical and translational research, and providing educational opportunities. 
Research 
 
Priority 7: Improve the relevance of clinical trials to older adults with cancer. 
Priority 8: Evaluate the benefits of geriatric assessment-allocated treatments and geriatric co-
management in improving treatment outcomes for older adults with cancer. 
Priority 9: Utilize personalized medicine technologies to enhance the precision of cancer 
understanding and management of older adults. 
Collaborations and partnerships 
 
Priority 10: Develop and strengthen links between SIOG & the geriatric oncology work force, 
international specialized agencies, global and regional professional organizations, policy makers, and 
patient advocacy groups. 
Priority 11: Promote the inclusion of specific provisions for delivering high-quality evidence-based care 
for older adults in national cancer control plans. 
Priority 12: Create global funding mechanisms aimed at fostering professional development of the 
geriatric oncology workforce and promoting research on the interface of cancer and aging.  
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